Subscribe to RSS
DOI: 10.1055/s-2001-15180
Serotonin, Norepinephrine and Dopamine Involvement in the Antidepressant Action of Hypericum Perforatum
Publication History
Publication Date:
31 December 2001 (online)
![](https://www.thieme-connect.de/media/pharmaco/200102/lookinside/thumbnails/10.1055-s-2001-15180-1.jpg)
Hypericum perforatum is considered an effective alternative to the synthetic antidepressants in the treatment of mild-to-moderate depression. Recently, we showed that the effects on neurotransmitter contents in different brain regions of laboratory animals are more evident after administration of hypericum extracts containing a higher concentration of flavonoids, thus suggesting that these compounds are important in the antidepressant action of hypericum perforatum. We studied the effects of Ph-50, a hypericum extract standardized to flavonoids (50 %) and containing 0.3 % hypericin and 4.5 % hyperforin on brain serotonin content, norepinephrine and dopamine by a high-performance liquid chromatography method in discrete brain areas (cortex, diencephalon and brainstem) in male Sprague-Dawley rats. Moreover, we evaluated the effects of Ph-50 alone or in association with sulpiride (a dopamine receptor antagonist), metergoline (a serotonin receptor antagonist) and 6-hydroxydopamine (6-OH-DA, destroying norepinephrine-containing neurons) using a forced-swimming test in the rat. Hypericum extract (Ph-50; 250 - 500 mg/kg) with acute oral administration enhanced serotonin, norepinephrine and dopamine content in the brain and reduced the immobility time of rats in the forced-swimming test. Sulpiride, metergoline and 6-OH-DA significantly increased the period of immobility in the forced-swimming test for the rats receiving hypericum extract (Ph-50). The results indicate that the neurotransmitters studied could be involved in the anti-immobility effects of hypericum, and suggest that its antidepressant action is probably mediated by serotonergic, noradrenergic and dopaminergic system activation.
References
- 1 Bladt S, Wagner H. Inhibition of MAO by fractions and constituents of hypericum extract. J Geriatric Psychiatr Neurol. 1994; 7 57-59
- 2 Bennett D A, Phun L, Polk J F, Voglino S A, Zlotnik V, Raffa R B. Neuropharmacology of St-John's Wort (Hypericum). Ann Pharmacother. 1998; 32 1201-1208
- 3 Butterweck V, Wall A, Lieflander-Wulf L, Winterhoff H, Nahrstedt A. Effects of the total extract and fractions of hypericum perforatum in animal assays for antidepressant activity. Pharmacopsychiatry. 1997; 30 (Suppl. 2) 117-124
- 4 Calapai G, Crupi A, Firenzuoli F, Inferrera G, Campo G M, Caputi A P. Effects of hypericum perforatum on levels of 5-Hydroxytryptamine. Noradrenaline and Dopamine in the cortex, diencephalon and brainstem of the rat. J Pharm Pharmacol. 1999; 51 723-728
- 5 Calapai G, Corica F, Corsonello A, Sautebin L, Di Rosa M, Campo G M, Buemi M, Nicita Mauro V, Caputi A P. Leptin increases serotonin turnover by inhibition of brain nitric oxide synthesis. J Clin Invest. 1999; 104 975-982
- 6 Cervo L, Grignaschi G, Rossi C, Samanin R. Role of central serotonergic neurons in the effect of sertraline in rats in the forced swimming test. Eur J Pharmacol. 1991; 196 217-222
- 7 Cott J M. In vitro receptor binding and enzyme inhibition by hypericum perforatum extract. Pharmacopsychiatry. 1997; 30 (Suppl. 2) 108-112
- 8 Delgado P, Moreno F. Antidepressants and the brain. Int din Psychopharmacol. 1999; 1 (Suppl. 14) 9-16
- 9 De Saint Blanquat G, Lambouef Y, Fritsch P. Determination of catecholamines in biological tissues by liquid chromatography with coulometric detection. fehlt. 1987; 415 388-392
- 10 Gobbi M, Dallavalle F, Ciapparelli C, Diomede L, Morazzoni P, Verotta L, Caccia S, Cervo L, Mennini T. Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex. Naunyn-Shmiedeberg's Archives of Pharmacology. 1999; 360 262-269
- 11 Grimaldi B, Bonnin A, Fillion M P, Prudhomme N, Fillion G. 5-Hydroxytriptamine-moduline: a novel endogenous peptide involved in the control of anxiety. Neuroscience. 1999; 93 1223-1225
- 12 Hantraye P. Modeling dopamine system dysfunction in experimental animals. Nucl Med Biol. 1998; 25 721-728
- 13 Hank S L. Locus coeruleus lesion by local 6-hydroxydopamine infusion causes marked and specific destruction of noradrenergic neurons, long-term depletion of norepinephrine and the enzymes that synthesize it, and enhanced dopaminergic mechanisms in the ipsilateral cerebral cortex. J Neurosci. 1984; 4 699-707
- 14 Harrer G, Schulz V. Clinical investigation of the antidepressant effectiveness of hypericum. J Geriatr Psychiatry Neurol. 1994; 7 (Suppl. 1) 6-8
- 15 Heinz A, Schmidt L G, Reischies F M. Anhedonia in schizophrenic, depressed, or alcohol-dependent patients-neurobiological correlates. Pharmacopsychiatry. 1994; 27 (Suppl. 1) 7-10
- 16 Josey E S, Tackett R L. St John's wort: a new alternative for depression?. Int J Clin Pharmacol Ther. 1999; 37 111-119
- 17 Kasper S. From symptoms to social functioning: differential effects of antidepressant therapy. Int Clin Psychopharmacol. 1999; 14 27-31
- 18 Leonard B E. Mechanisms of action of antidepressants. CNS Drugs. 1995; 4 (Suppl. 1) 1-12
- 19 Linde K, Ramirez G, Mulrow C D, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression - an overview and meta-analysis of randomized clinical trials. Brit Med J. 1996; 313 253-258
- 20 Lookmann G, Schille C, Baghal T, Kleser M. St. John's Wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy. Pharmacopsychiatry. 1998; 31 54-59
- 21 Lucki I. The forced-swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol. 1997; 8 523-532
- 22 Montgomery S A. Predicting response: norepinephrine reuptake inhibition. Int Clin Psychopharmacol. 1999; I (Suppl. 14) 21-26
- 23 Muller W E, Kasper S. Clinically used antidepressant drugs. Pharmacopsychiatry. 1997; 2 (Suppl. 30) 71
- 24 Muller W E, Rolli M, Schafer C, Hafner U. Effects of hypericum extract (Li 160) in biochemical models of antidepressant activity. Pharmacopsychiatry. 1997; 30 (Suppl. 2) 102-107
- 25 Muller W E, Singer A, Wonnemann M, Hafner U, Rolli M, Schafer C. Hyperforin represents the neurotransmitter reuptake inhibiting constituent of hypericum extract. Pharmacopsychiatry. 1998; 31 (Suppl. 1) 16-21
- 26 Nathan P. The experimental and clinical pharmacology of St. John's Wort (Hypericum perforatum L.) Mol. Psychiatry. 1999; 4 333
- 27 Paxinos F, Watson C. The Rat Brain in Stereotaxic Coordinates. Academic Press London 1986
- 28 Porsolt R D, Anton G, Blavet N, Jafre M. Behavioral despair in rats: A new model sensitive to antidepressant. Eur J Pharmacol. 1978; 47 379-391
- 29 Squadrito F, Calapai G, Altavilla D, Cucinotta D, Zingarelli B, Arcoraci V, Campo G M, Capuli A P. Central serotonergic system involvement in the anorexia induced by NG nitro-L-arginine, an inhibitor of nitric oxide synthase. Eur J Pharmacol. 1994; 255 51
- 30 Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H. Inhibition of monoamine oxidase by hypericin. Planta Med. 1984; 50 272-274
- 31 Vitiello B. Hypericum perforatum extracts as potential antidepressants. J Pharm Pharmacol. 1999; 51 513-517
- 32 Volz H P. Controlled clinical trials of hypericum extracts in depressed patients - an overview. Pharmacopsychiatry. 1997; 2 (Suppl. 2) 72-76
- 33 Wheatley D. Li 160, an extract of St. John's wort, versus amitriptyline in mildly to moderately depressed outpatients - a controlled 6-week clinical trial. Pharmacopsychiatry. 1997; 2 (Suppl. 30) 77
- 34 Wheatley D. Hypericum extract-Potential in the treatment of depression. CNS Drugs. 1998; 9 431-440
- 35 Wheatly P. Hypericum in seasonal affective disorder (SAD). Curr Med Opin. 1999 a; 15 33-37
- 36 Willner P. The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol. 1997; 3 (Suppl. 12) 7-14
- 37 Zuardi A W. 5-HT related drugs and human experimental anxiety. Neurosci Biobehav Rev. 1990; 14 507-510
Gioacchino Calapai, MD
Institute of Pharmacology
School of Medicine, University of Messina
Via Consolare Valeria 49
Policlinico Universitario - Torre Biologica 5° Piano
98124 - Messina
Italy
Phone: 090/2213646
Fax: 090/2213300
Email: gcalapai@unime.it